Pathological response to neoadjuvant gemcitabine plus nabpaclitaxel in pancreatic adenocarcinoma to improve survival.

Alvarez-Gallego, Rafael; Cubillo, Antonio; Garralda, Elena; Vega, Estela; Rodríguez-Pascual, Jesús; Ugidos, Lisardo; Vicente, Emilio; Quijano, Yolanda; Rubio, Carmen; Hernando, O.; Plaza, Carlos; López‐Ríos, Fernando; Hidalgo, Manuel

doi:10.1200/jco.2016.34.15_suppl.4109

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With FOLFIRINOX, overall response rate reported range from 30% to 50%[ 54 , 55 ], resection rates 40%-50%[ 56 - 58 ] with 40%-90% having R0 resection[ 57 - 59 ]. In similar patient groups gemcitabine and nab paclitaxel, has a response rate of 30%[ 60 , 61 ] with resection rate of 56% and R0 resection rate of 80%[ 61 ].…”

Section: Resultsmentioning

confidence: 99%

Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?

Lee

Kanhere

Trochsler

et al. 2018

WJGO

View full text Add to dashboard Cite

AIMTo analyse the safety and efficacy of curative intent surgery in biliary and pancreatic cancer.METHODSAn extensive literature review was performed using MEDLINE, Google Scholar and EMBASE to identify articles regarding hepato-pancreatoduodenectomy or resection of liver metastasis in patients with pancreatic, biliary tract, periampullary and gallbladder cancers.RESULTSA total of 19 studies were identified and reviewed. Major hepatectomy was undertaken in 391 patients. The median overall survival for pancreatic cancer ranged from 5-36 mo and for biliary tract/gallbladder cancer, it was 8-38 mo. The 30 d mortality rate was only 1%-9%. Overall Survival was significantly better for patients, who had good response to neoadjuvant chemotherapy, underwent metachronous liver resection and who had intestinal type tumours.CONCLUSIONResection of liver metastases in pancreatic and biliary cancers may provide survival benefit without compromising safety and quality of life in a very select group of patients. These data may be utilised to formulate selection criteria that may allow future investigation of resection in the era of more effective systemic therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?

Lee

Kanhere

Trochsler

et al. 2018

WJGO

View full text Add to dashboard Cite

show abstract

“…Nevertheless, registry data (excluding borderline resectable patients) yield median survival of 13–16 months, which compares favorably to our results. 6,26 However, the efficacy portion of this study is limited by the small sample size and, furthermore, unintended bias toward a positive result in an industry-sponsored study.…”

Section: Discussionmentioning

confidence: 99%

Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma

Rosemurgy

Ross

Vitulli

et al. 2017

Journal of Pancreatic Cancer

View full text Add to dashboard Cite

Purpose: This is a first-in-man safety study in locally advanced pancreatic cancer (LAPC) using a targeted intra-arterial delivery catheter (RenovoCath™).Methods: Twenty patients were enrolled in a four-stage dose escalation of intra-arterial, locally delivered gemcitabine, at doses up to 1000 mg/m2. Patients' symptoms and laboratory values were monitored for safety and tolerability. Secondary endpoints included the effect on tumor size, tumor markers, and survival.Results: One hundred one treatments were administered to 20 patients. Five patients dropped out early due to adverse events or withdrawing consent. Serious adverse events and complications were as follows: sepsis (n = 3), grade 3 neutropenia (n = 3), guide-mediated vascular dissection (n = 3), and pulmonary toxicity (n = 1). There were no cases of elevated liver or pancreatic enzymes. All sepsis cases occurred in patients with biliary stent/drains, prompting the addition of periprocedural treatment with antibiotics, which effectively prevented further sepsis in the study. Efficacy analysis was limited to 15 patients who received more than two treatments. Fifty-eight percent of these patients had a reduction in CA 19-9 tumor markers, 3 patients had tumor progression, 1 had partial response, and 11 showed disease stability. The survival rate at 12 months was 60%.Conclusions: The results demonstrate feasibility of localized and selective intra-arterial chemotherapy delivery to the pancreas utilizing the RenovoCath. With gemcitabine, this approach is safe, with the sole prerequisite of perioperative antibiotics for patients with prior biliary drainage/stent. Efficacy results suggest a survival benefit when compared to historical control, especially in patients with prior radiation therapy.

show abstract

Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma

Rosemurgy

Ross

Vitulli

et al. 2017

Journal of Pancreatic Cancer

View full text Add to dashboard Cite

Pathological response to neoadjuvant gemcitabine plus nabpaclitaxel in pancreatic adenocarcinoma to improve survival.

Cited by 4 publications

References 0 publications

Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?

Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?

Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma

Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma

Contact Info

Product

Resources

About